LAST WEEK TODAY!

A summary of what was published on ProstateWarriors.com during the past week

Here I am with the third newsletter from the site. I have a hope: this week I found little new information about ongoing or starting clinical trials. I have a feeling that this might be because the “breaking news,” especially those that can influence stock prices, tend to come towards the end of the year, also because December will host some quite important oncology conventions!

We also have a podcast if you prefer to listen to the newsletter, you can find it HERE.​

Clinical Research

• CAPItello-281 Trial: Targeting PTEN-Deficient mHSPC
  ​This phase III trial investigated the use of Truqap (capivasertib), an AKT inhibitor, in combination with abiraterone and androgen deprivation therapy (ADT) for men with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC). The trial demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) in the Truqap group compared to the placebo group. While overall survival (OS) data is not yet mature, early analysis shows a trend towards improvement in the Truqap group. The study highlights the potential of AKT inhibitors in treating PTEN-deficient mHSPC, a subtype with a worse prognosis, affecting approximately 25% of mHSPC patients. Complete results will be presented at a future medical meeting and shared with regulatory authorities.
  ​
• Investigating the Link Between LDL-C Levels and Prostate Cancer RiskÂ​
  A cross-sectional study using data from the National Health and Nutrition Examination Survey (NHANES) explored the relationship between blood LDL-C levels and prostate cancer risk in non-hypertensive men. The study found no significant link between LDL-C levels and prostate cancer risk overall. However, a subgroup analysis indicated that lower LDL-C levels were associated with an increased risk of prostate cancer in non-hypertensive participants. The study also revealed a threshold effect, with the risk of prostate cancer increasing when LDL-C levels dropped below 67 mg/dl in these men. Additionally, the use of cholesterol-lowering prescription drugs was linked to a higher risk of prostate cancer in this group.
  ​
• ISM5939: AI-Designed Cancer Drug Enters Clinical Trials​
  Insilico Medicine received FDA approval for an Investigational New Drug (IND) application for ISM5939, an oral small molecule inhibitor targeting ENPP1 for the treatment of solid tumors. This milestone marks the tenth AI-driven molecule developed by Insilico to receive clearance for clinical trials. This achievement validates the transformative potential of AI in accelerating drug development and bringing innovative treatments to patients faster. This is BIG! This is really big, for all diseases.

Preclinical Research

• NP18: A Novel PROTAC Targeting AR-V7​
  Researchers have developed NP18, a first-in-class, highly potent, non-covalent PROTAC that targets the N-terminal domain (NTD) of the androgen receptor (AR). This is significant because existing AR-targeting PROTACs focus on the ligand-binding domain (LBD), making them ineffective against AR-V7, a variant lacking the LBD often associated with treatment resistance. NP18 effectively degrades both full-length AR (AR-FL) and AR-V7, exhibiting promising antitumor activity in preclinical models, including patient-derived xenograft (PDX) models. Its ability to simultaneously inhibit all clinically relevant AR variants, including AR-FL, AR mutants, and AR-V7, positions it as a potential solution to overcome resistance mechanisms6. A potential heavy weapon!
  ​
• Kaempferol: A Potential Treatment for Prostate Cancer Metastasis
  ​Preclinical studies have identified kaempferol, a key active ingredient in the traditional Chinese medicine formula Chaihu-Shugan-San (CSS), as a potential therapeutic agent for prostate cancer metastasis. Kaempferol has demonstrated the ability to enhance α2M secretion in bone marrow-derived macrophages (BMDMs), inhibit prostate cancer cell migration, and suppress the nuclear translocation of GR and the GR/PER1 pathway. NOTE: kaempferol is found in many vegetables that we consume daily!.
  ​
• “3-in-1” Antibody: A Paradigm Shift in Cancer Treatment​
  A novel “3-in-1” antibody design has emerged as a potential game-changer in cancer treatment, combining targeting, drug delivery, and immune activation. Preclinical studies in mice have shown prolonged survival and complete cancer remission at higher doses, suggesting its safety and effectiveness. This personalized immunotherapy approach offers hope for a safer, more effective, and accessible treatment option for cancer patients worldwide. Its modular design allows for in-hospital customization of patient-specific peptides, tailoring the treatment to individual tumor profiles.

And…that’s all folks! For today at least!
Please let me know if there is anything I can improve in my newsletters, and let me know if you have enjoyed the podcast.

If you this newsletter was delivered to your SPAM folder, make sure to let your email system know that it is not spam.
​
​
Have a great weekend!

Max